Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation.

Ritari J, Hyvärinen K, Koskela S, Itälä-Remes M, Niittyvuopio R, Nihtinen A, Salmenniemi U, Putkonen M, Volin L, Kwan T, Pastinen T, Partanen J.

Leukemia. 2019 Jan;33(1):240-248. doi: 10.1038/s41375-018-0229-3. Epub 2018 Aug 8.

2.

Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.

Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG.

Haematologica. 2016 Jun;101(6):764-72. doi: 10.3324/haematol.2015.138990. Epub 2016 Apr 1.

3.

Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.

Petersdorf EW, Malkki M, Horowitz MM, Spellman SR, Haagenson MD, Wang T.

Blood. 2013 Mar 7;121(10):1896-905. doi: 10.1182/blood-2012-11-465161. Epub 2013 Jan 10.

4.

Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.

Faridi RM, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, Daly A, Berka N, Storek J, Masood Khan F.

PLoS One. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242. eCollection 2016.

5.

Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, Ozawa Y, Kawano I, Atsuta Y, Kato K, Ichinohe T, Inoue M, Teshima T; JSHCT GVHD Working Group.

Haematologica. 2016 Dec;101(12):1592-1602. Epub 2016 Aug 4.

6.

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ.

Blood. 2015 Feb 19;125(8):1333-8. doi: 10.1182/blood-2014-10-609032. Epub 2015 Jan 15.

7.

Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang LM, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H.

Haematologica. 2012 Dec;97(12):1804-12. doi: 10.3324/haematol.2012.066159. Epub 2012 Jun 24.

8.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

9.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

10.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.

PMID:
24748537
11.

Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.

Rockstroh A, Al-Ali HK, Lange T, Pönisch W, Krahl R, Cross M, Behre G, Niederwieser D, Pfrepper C.

J Cancer Res Clin Oncol. 2015 Dec;141(12):2193-203. doi: 10.1007/s00432-015-2003-5. Epub 2015 Jul 1.

PMID:
26129640
12.

Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation.

Dobbelstein C, Ahn KW, Haagenson M, Hale GA, van Rood JJ, Miklos D, Waller EK, Spellman SR, Fernandez-Vina M, Ganser A, Aljurf M, Bornhaeuser M, Gupta V, Marino SR, Pollack MS, Reddy V, Eder M, Lee SJ.

Biol Blood Marrow Transplant. 2013 May;19(5):741-5. doi: 10.1016/j.bbmt.2013.01.020. Epub 2013 Feb 1.

13.

Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.

Zhu X, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Zhang J, Ye X, Lin M, Cai Z, Huang H.

Leuk Res. 2013 Sep;37(9):1046-51. doi: 10.1016/j.leukres.2013.06.016. Epub 2013 Jul 10.

PMID:
23849987
14.

Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.

Bornhäuser M, Theuser C, Soucek S, Hölig K, Klingebiel T, Blau W, Fauser A, Runde V, Schwinger W, Rutt C, Ehninger G.

Haematologica. 2000 Aug;85(8):839-47.

15.

Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.

Rovó A, Daikeler T, Halter J, Heim D, Tsakiris DA, Stern M, Waltimo T, Studt JD, Tyndall A, Gratwohl A, Tichelli A.

Haematologica. 2011 Jan;96(1):150-5. doi: 10.3324/haematol.2010.030874. Epub 2010 Sep 17.

17.

The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation.

Zhao XS, Wang Y, Yan CH, Wang JZ, Zhang XH, Xu LP, Liu KY, Huang XJ.

Clin Transplant. 2014 Aug;28(8):926-34. doi: 10.1111/ctr.12404. Epub 2014 Jul 7.

PMID:
24931494
18.

Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.

Meisel R, Enczmann J, Balzer S, Bernbeck B, Kramm C, Schönberger S, Sinha K, Tröger A, Wernet P, Göbel U, Laws HJ, Dilloo D.

Klin Padiatr. 2005 May-Jun;217(3):135-41.

PMID:
15858704
19.

Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.

Simonetta F, Masouridi-Levrat S, Beauverd Y, Tsopra O, Tirefort Y, Koutsi A, Stephan C, Polchlopek-Blasiak K, Pradier A, Dantin C, Ansari M, Roosnek E, Chalandon Y.

Leuk Lymphoma. 2018 Mar;59(3):590-600. doi: 10.1080/10428194.2017.1344844. Epub 2017 Jul 6.

PMID:
28679328

Supplemental Content

Support Center